SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jgideon who wrote (2613)10/10/2000 9:14:34 AM
From: DanZ  Read Replies (1) of 5582
 
The problem with the supply last year was that they didn't have enough bottles. Also, they didn't know how much demand to expect, and it would have been very risky given last year's cash position to produce excessive inventory without knowing the demand. They now have a good idea how much demand to expect and have plenty supply of bottles and other materials on hand to make Zicam. They also have $4 to $5 million in finished goods at their cost ready to ship and can produce about 100,000 bottles per day if needed. It is my understanding that they also have three additional manufacturers ready to go if they need more supply than Botanicals can provide. The supply problem from last year should not be repeated.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News